Clinical Trial Update: A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on CAN106 assessing safety, tolerability, efficacy, PK, and PD in subjects with paroxysmal nocturnal hemoglobinuria (PNH) and hemolysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolysis
• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• CAN106

Snippet

Sponsor: CARE Pharma Shanghai Ltd. | Conditions: PNH, Hemolysis | Phase 1, Phase 2 | Status: UNKNOWN